Form 4: Ionis Pharmaceuticals Director Receives Stock Option Grant

Director Peter N. Reikes was granted 10,753 non-qualified stock options in Ionis Pharmaceuticals, Inc. as part of the company's director compensation plan.

Summary

• Director Peter N. Reikes received a grant of 10,753 non-qualified stock options on June 4, 2026.
• The options have an exercise price of $75.13 per share.
• The grant was issued under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest in three equal annual installments starting June 4, 2027, becoming fully vested on June 4, 2029.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized toward long-term company performance.

Comparison to Industry Standards

• The use of a multi-year vesting schedule (three years) is consistent with standard industry practices for director compensation to encourage retention and long-term oversight.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of the first installment of options on June 4, 2027.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Stock Options, Director Compensation, Insider Transaction